TYZAVAN ™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation ...

LONDON, May 1, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) the multinational pharmaceutical ...

LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to ...

Hikma is introducing the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name Tyzavan. “The approval of Tyzavan underscores our team’s exceptional R&D ...

Tyzavan can be stored at room temperature and has a shelf life of 16 months. The Food and Drug Administration (FDA) has approved Tyzavan ™ (vancomycin injection, USP), a novel ready-to-infuse, room ...

Tyzavan is supplied as a single-dose bag in 7 presentations allowing for dosing flexibility. Tyzavan ™ (vancomycin injection), a ready-to-infuse, room temperature stable formulation of vancomycin, is ...

Hikma has obtained permission from the Food and Drug Administration for a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name Tyzavan ...

LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix ...

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...

Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...